Drug Trial Radar · NCT07944547
APL-1702 Photodynamic Therapy in Patients With High-Risk HPV-Positive Cervical Intraepithelial Neoplasia Grade II/III (CIN2/3)
Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
159
Planned (sponsor's estimate)
Start
May 26, 2025
Primary completion
Jan 2028
Study completion Jul 2029
Sponsor
- Lead sponsor
- Xiangya Hospital of Central South UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Nov 18, 2026
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This investigator-initiated, open-label, exploratory study evaluates the safety and preliminary efficacy of APL-1702 photodynamic therapy in participants with high-risk human papillomavirus (hrHPV)-positive cervical intraepithelial neoplasia grade 2 (CIN2) or grade 3 (CIN3). Part 1 enrolls adults with CIN2 into six treatment-regimen groups to identify a preferred regimen, primarily on the basis of histological regression at Week 24 after the first treatment. Part 2 enrolls adults aged 18 to 45 years with hrHPV-positive CIN3 and evaluates three treatments administered at Day 0, Month 1, and Month 3. Participants are assessed for histological regression, hrHPV clearance, and safety.
Conditions
- Cervical Intraepithelial Neoplasia Grade 2/3
- Human Papillomavirus Infection
Interventions
APL-1702Drug
APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed. Regimen: Q3W x 3.
APL-1702Drug
APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed. Regimen: Q3W x 6.
APL-1702Drug
APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed. Regimen: Q2W x 3.
APL-1702Drug
APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed. Regimen: Q2W x 6.
APL-1702Drug
APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed. Regimen: Q1W x 3.
APL-1702Drug
APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed. Regimen: Q1W x 6.
APL-1702Drug
APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed. Regimen: Day 0, Month 1, and Month 3 (3 treatments total).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1: Histological regression rate at Week 24 after the first treatmentTime frame: Week 24 after the first treatment
- Part 2: Histological regression rate at Week 24 after the first treatmentTime frame: Week 24 after the first treatment
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Xiangya Hospital of Central South University
Changsha, Hunan, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.